MXPA03010255A - Ligandos heterobiciclicos de proteinas de union a fk-506. - Google Patents

Ligandos heterobiciclicos de proteinas de union a fk-506.

Info

Publication number
MXPA03010255A
MXPA03010255A MXPA03010255A MXPA03010255A MXPA03010255A MX PA03010255 A MXPA03010255 A MX PA03010255A MX PA03010255 A MXPA03010255 A MX PA03010255A MX PA03010255 A MXPA03010255 A MX PA03010255A MX PA03010255 A MXPA03010255 A MX PA03010255A
Authority
MX
Mexico
Prior art keywords
compound
mmol
pharmaceutically acceptable
substituted
product
Prior art date
Application number
MXPA03010255A
Other languages
English (en)
Spanish (es)
Inventor
Kathleen Fay Lorraine
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of MXPA03010255A publication Critical patent/MXPA03010255A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA03010255A 2001-05-10 2002-05-10 Ligandos heterobiciclicos de proteinas de union a fk-506. MXPA03010255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28982801P 2001-05-10 2001-05-10
PCT/US2002/014966 WO2002089806A1 (en) 2001-05-10 2002-05-10 Heterobicycles fkbp-ligands

Publications (1)

Publication Number Publication Date
MXPA03010255A true MXPA03010255A (es) 2005-03-07

Family

ID=23113278

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010255A MXPA03010255A (es) 2001-05-10 2002-05-10 Ligandos heterobiciclicos de proteinas de union a fk-506.

Country Status (6)

Country Link
EP (1) EP1423119A4 (https=)
JP (1) JP2004532854A (https=)
BR (1) BR0210060A (https=)
CA (1) CA2446795A1 (https=)
MX (1) MXPA03010255A (https=)
WO (1) WO2002089806A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614944A2 (pt) * 2005-08-19 2011-04-26 Elan Pharm Inc inibidores sulfonamido n-bicìclicos ponte de gama-secretase
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
EP2899192A1 (en) * 2014-01-24 2015-07-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
MX2016016190A (es) 2014-08-27 2017-03-08 Hoffmann La Roche Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.
US10597378B2 (en) 2017-09-08 2020-03-24 National Health Research Institutes Tetrahydroisoquinolines for use as MOR/NOP dual agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880927A (en) * 1972-06-19 1975-04-29 Lilly Co Eli {62 -Phenyl-{62 ,{62 -difluoroethylamines
PT1098897E (pt) * 1998-07-17 2004-10-29 Agouron Pharma Compostos composicoes e metodos para estimular o crescimento e a elongacao neuronal
US6818643B1 (en) * 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
AU2001292160A1 (en) * 2000-10-19 2002-04-29 Pfizer Products Inc. Bridged piperazine derivatives
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
EP1423119A1 (en) 2004-06-02
WO2002089806A1 (en) 2002-11-14
JP2004532854A (ja) 2004-10-28
BR0210060A (pt) 2004-08-17
EP1423119A4 (en) 2005-04-13
CA2446795A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
JP4361566B2 (ja) 縮合キノリン誘導体およびその使用
ES2883701T3 (es) Agonistas del receptor 2 del péptido formilado de ciclopropil urea y agonistas del receptor 1 del péptido formilado
JP2022539579A (ja) Plk1の選択的分解誘導化合物
JP7431778B2 (ja) ヒト血漿カリクレイン阻害剤
AU2004255183A1 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
US6544987B2 (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation
CA3105681A1 (en) Pyridazinone derivative
CN106536491B (zh) 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
JP5139307B2 (ja) ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
MXPA04005861A (es) Compuestos antagonistas selectivos de pirrolopirimidina a2b, su sintesis y uso.
JP3620644B2 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤
AU2008284746A1 (en) Aminopyrazole amide derivative
IL302665A (en) Bicyclic 1,4-diazepenones and their therapeutic uses
ES2381686T3 (es) Derivados de alfa-aminocarboxamida cuaternarios como moduladores de canales de sodio con apertura por voltaje
AU2020290485A1 (en) Progranulin modulators and methods of using the same
MXPA03010255A (es) Ligandos heterobiciclicos de proteinas de union a fk-506.
US20020065292A1 (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity
US7795267B2 (en) Bicyclic piperazine compound having TGR23 antagonistic activity
CN113754635A (zh) 稠环类化合物及其制备方法和用途
CA3247233A1 (en) T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND THEIR METHODS OF USE
WO2021127303A1 (en) Progranulin modulators and methods of using the same
JP4214524B2 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤
JP2005306839A (ja) 二環性ピペラジン化合物およびその用途